Literature DB >> 24982084

In vitro antifungal susceptibility profile and correlation of mycelial and yeast forms of molecularly characterized Histoplasma capsulatum strains from India.

Shallu Kathuria1, Pradeep K Singh1, Jacques F Meis2, Anuradha Chowdhary3.   

Abstract

The antifungal susceptibility profiles of the mycelial and yeast forms of 23 Histoplasma capsulatum strains from pulmonary and disseminated histoplasmosis patients in India are reported here. The MIC data of this dimorphic fungus had good agreement between both forms for azoles, amphotericin B, and caspofungin. Therefore, the use of mycelial inocula for H. capsulatum antifungal susceptibility testing is suggested, which is less time-consuming vis-à-vis the yeast form, which requires 6 to 8 weeks for conversion.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24982084      PMCID: PMC4135809          DOI: 10.1128/AAC.02973-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome.

Authors:  L J Wheat; P Connolly; M Smedema; E Brizendine; R Hafner
Journal:  Clin Infect Dis       Date:  2001-10-23       Impact factor: 9.079

2.  In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

Authors:  G S Kobayashi; S J Travis; M G Rinaldi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

3.  Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America.

Authors:  J Wheat; G Sarosi; D McKinsey; R Hamill; R Bradsher; P Johnson; J Loyd; C Kauffman
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

4.  Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model.

Authors:  S Kohler; L J Wheat; P Connolly; C Schnizlein-Bick; M Durkin; M Smedema; J Goldberg; E Brizendine
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

Review 5.  Disseminated histoplasmosis in an apparently immunocompetent individual from north India: a case report and review.

Authors:  Sushruta Kathuria; Malini Rajinder Capoor; Sachin Yadav; Avninder Singh; V Ramesh
Journal:  Med Mycol       Date:  2013-04-03       Impact factor: 4.076

6.  Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial.

Authors:  F M Hecht; J Wheat; A H Korzun; R Hafner; K J Skahan; R Larsen; M T Limjoco; M Simpson; D Schneider; M C Keefer; R Clark; K K Lai; J M Jacobson; K Squires; J A Bartlett; W Powderly
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-10-01

7.  Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum.

Authors:  J Wheat; P Marichal; H Vanden Bossche; A Le Monte; P Connolly
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

8.  Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5' end of the large-subunit (26S) ribosomal DNA gene.

Authors:  C P Kurtzman; C J Robnett
Journal:  J Clin Microbiol       Date:  1997-05       Impact factor: 5.948

Review 9.  In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

Authors:  Ana Espinel-Ingroff
Journal:  Rev Iberoam Micol       Date:  2003-12       Impact factor: 1.044

10.  In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms.

Authors:  Toru Nakai; Jun Uno; Fumiaki Ikeda; Shuichi Tawara; Kazuko Nishimura; Makoto Miyaji
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

View more
  7 in total

1.  Antifungal therapeutics for dimorphic fungal pathogens.

Authors:  Kristie D Goughenour; Chad A Rappleye
Journal:  Virulence       Date:  2016-09-19       Impact factor: 5.882

2.  Antifungal Susceptibility of Emerging Dimorphic Pathogens in the Family Ajellomycetaceae.

Authors:  Karolina Dukik; Abdullah M S Al-Hatmi; Ilse Curfs-Breuker; Dirk Faro; Sybren de Hoog; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Cutaneous Manifestation of Underlying Disseminated Histoplasmosis in an Immunocompetent Host of Nonendemic Area with Reversible CD4 Cell Depletion and its Recovery on Antifungal Therapy.

Authors:  Praveen Bharti; Kiran Bala; Naresh Gupta
Journal:  Mycopathologia       Date:  2015-04-17       Impact factor: 2.574

Review 4.  An Unusual Presentation of Disseminated Histoplasmosis: Case Report and Review of Pediatric Immunocompetent Patients from India.

Authors:  Poojan Agarwal; Malini R Capoor; Mukul Singh; Arpita Gupta; Arini Chhakchhuak; Pradeep Debatta
Journal:  Mycopathologia       Date:  2015-07-01       Impact factor: 2.574

5.  In Vitro Antifungal Susceptibility of Yeast and Mold Phases of Isolates of Dimorphic Fungal Pathogen Emergomyces africanus (Formerly Emmonsia sp.) from HIV-Infected South African Patients.

Authors:  Tsidiso G Maphanga; Erika Britz; Thokozile G Zulu; Ruth S Mpembe; Serisha D Naicker; Ilan S Schwartz; Nelesh P Govender
Journal:  J Clin Microbiol       Date:  2017-03-29       Impact factor: 5.948

6.  Evaluation of the Anti-Histoplasma capsulatum Activity of Indole and Nitrofuran Derivatives and Their Pharmacological Safety in Three-Dimensional Cell Cultures.

Authors:  Carolina Orlando Vaso; Níura Madalena Bila; Fabiana Pandolfi; Daniela De Vita; Martina Bortolami; Jean Lucas Carvalho Bonatti; Rosângela Aparecida De Moraes Silva; Larissa Naiara Carvalho Gonçalves; Valeria Tudino; Roberta Costi; Roberto Di Santo; Maria José Soares Mendes-Giannini; Caroline Barcelos Costa-Orlandi; Luigi Scipione; Ana Marisa Fusco-Almeida
Journal:  Pharmaceutics       Date:  2022-05-12       Impact factor: 6.525

7.  Synthesis and Evaluation of the Antifungal and Toxicological Activity of Nitrofuran Derivatives.

Authors:  Carolina Orlando Vaso; Fabiana Pandolfi; Níura Madalena Bila; Daniela De Vita; Martina Bortolami; Maria José Soares Mendes-Giannini; Valeria Tudino; Roberta Costi; Caroline Barcelos Costa-Orlandi; Ana Marisa Fusco-Almeida; Luigi Scipione
Journal:  Pharmaceutics       Date:  2022-03-08       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.